Platelet-Derived Growth Factor: Physiology and What Research Reports

What platelet-derived growth factor is

Platelet-derived growth factor (PDGF) is a family of secreted signalling proteins, not a single molecule. Four gene products — the A, B, C and D chains — assemble into disulphide-linked dimers, giving the isoforms PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD. These dimers bind and activate two cell-surface receptor tyrosine kinases, PDGFRα and PDGFRβ, which then trigger intracellular cascades associated with cell division, migration and survival. The family took its name from the fact that the activity was first identified in serum from clotted blood, where platelets release it.

PDGF is often grouped with "peptides" in casual discussion, but structurally it sits with the larger growth-factor proteins rather than with the short synthetic peptides that dominate that conversation. Each mature chain is dozens of amino acids longer than a typical research peptide, and the biologically active unit is a dimer.

Where PDGF is produced and what it does

Platelet alpha granules are the classic reservoir: when platelets degranulate at a site of vessel injury, PDGF is among the factors released into the wound environment. Beyond platelets, PDGF chains are expressed by endothelial cells, macrophages, keratinocytes, vascular smooth muscle cells, fibroblasts and various epithelia, and expression typically rises during injury, inflammation and tissue remodelling.

The receiving cells are largely of mesenchymal or glial lineage — fibroblasts, vascular smooth muscle cells, pericytes, mesenchymal stromal cells, chondrocytes and certain neural progenitors. In broad physiological terms, PDGF signalling is associated with recruiting these cells into a repairing tissue, supporting the pericyte coverage of new microvessels, and driving the production of extracellular matrix. That combination is why the family appears so often in studies of wound repair, fibrosis, bone and tendon healing, and vascular remodelling.

Isoforms and their usual receptor partners

How PDGF is measured and studied

Research groups approach PDGF in several distinct ways, and the method shapes what the findings can mean:

• Expression profiling in tissue. Immunohistochemistry and related staining are used to ask whether the ligand or its receptor is present in a lesion. Researchers examined PDGF and its receptor in canine and feline meningiomas and reported detectable expression in those tumour tissues (PMID 37558425), and a separate study assessed CD117 and PDGFRα expression in patients with alopecia areata (PMID 32461384).
• Adding recombinant protein to cultured cells. This is how proliferation, migration and differentiation responses are characterised in vitro.
• Blocking or deleting the signal. Pathway inhibition in animal models tests whether PDGF signalling is required for a process, as in a zebrafish retina study (PMID 32251708).
• Delivery engineering. Because free growth factor is short-lived in tissue, much modern work focuses on carriers — fibres, gels and nanocapsules — that control how quickly PDGF is released (PMID 38263812).
• Clinical correlation. Ligand or receptor levels are compared against disease stage or outcome, as in an analysis of PDGF-C and PDGF-D in gastric cancer (PMID 26788156).

What the literature reports

Wound and soft-tissue repair

Chronic wounds are the setting in which PDGF has been studied most intensively as a therapeutic protein. A 2024 study described PDGF-loaded nanocapsules with tunable controlled release and reported improved chronic wound healing in its experimental model (PMID 38263812). In tendon, researchers modified electrospun fibres with PDGF-AA and reported that the construct promoted tendon healing (PMID 36411499). Both reports are device-and-protein combinations rather than tests of the free growth factor alone, which matters when interpreting them.

Bone and joint models

In an in vivo model of titanium-particle-induced osteolysis — a problem relevant to implant loosening — the study reported that PDGF-BB attenuated the bone loss observed (PMID 27776448). In rat osteoarthritis models, researchers reported anti-inflammatory and chondroprotective effects of PDGF-BB (PMID 35640164). These are animal findings and do not establish what happens in human joints.

Cell differentiation

PDGF-BB has been used as a differentiation cue in culture. One study reported that PDGF-BB stimulated differentiation of rat immature Leydig cells (PMID 29259043), and another reported that laminin combined with PDGF-BB promoted neuronal differentiation of human urine-derived stem cells (PMID 30603547). In a regenerative context, researchers reported that PDGF signalling contributed to retina regeneration in zebrafish (PMID 32251708).

Vascular cells and pericytes

PDGF-BB is a standard laboratory stimulus for vascular smooth muscle cells. A 2024 report — since retracted, which readers should note when weighing it — described rosuvastatin suppressing PDGF-BB-induced vascular smooth muscle cell proliferation and migration via MAPK signalling (PMID 38223321). In human tissue, a study reported that PDGF activated pericytes in the microvessels of chronic subdural haematoma outer membranes (PMID 38030262), illustrating that the same signalling can participate in an unwanted process as easily as a helpful one.

Tumour biology

Because PDGF receptors drive proliferation, the pathway is examined in oncology. Researchers reported clinical significance for PDGF-C and PDGF-D in gastric cancer (PMID 26788156), and PDGF with its receptor was detected in canine and feline meningiomas (PMID 37558425). This is a major reason the literature treats systemic growth-factor stimulation with caution rather than enthusiasm.

PDGF in research models: what studies report

The verified studies summarised here were designed to characterise biology or local delivery, not to profile systemic safety, and their abstracts do not report a human adverse-event dataset. What the body of work does highlight indirectly is a mechanistic tension: the same pathway associated with repair in bone and tendon models (PMID 27776448) is also associated with smooth muscle cell proliferation and migration in vascular experiments (PMID 38223321), pericyte activation in haematoma membranes (PMID 38030262) and tumour-associated expression (PMID 26788156). Interpretation of any PDGF finding therefore depends heavily on whether delivery was local and controlled or systemic.

Why the term reaches non-specialist readers

PDGF appears on ingredient lists and discussion boards mainly through three routes: platelet-rich plasma preparations, where it is one of the factors platelets release; regulatory-approved topical products, since a recombinant human PDGF-BB gel exists as a prescription wound product in the United States; and receptor-directed oncology drugs that inhibit PDGFR alongside other kinases. Recombinant PDGF sold for laboratory work is supplied for research use only. None of the studies cited here support extrapolating from a cell-culture or rodent result to a person.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or treatment decision. Readers evaluating PDGF literature should note that most of the above evidence is preclinical, that delivery vehicles often account for much of the reported effect, and that at least one cited paper has been retracted.

References

• Platelet-derived growth factor-BB attenuates titanium-particle-induced osteolysis in vivo (Growth Factors, 2016)
• Platelet-derived growth factor AA-modified electrospun fibers promote tendon healing (Journal of Biomaterials Applications, 2023)
• Platelet-derived growth factor BB stimulates differentiation of rat immature Leydig cells (Journal of Molecular Endocrinology, 2018)
• The expression of platelet-derived growth factor and its receptor in canine and feline meningiomas (Journal of Veterinary Medical Science, 2023)
• Contribution of platelet-derived growth factor signaling to retina regeneration in zebrafish (Neuroscience Letters, 2020)
• Platelet-derived Growth Factor Activates Pericytes in the Microvessels of Chronic Subdural Hematoma Outer Membranes (Neurologia Medico-Chirurgica, 2024)
• Platelet-Derived Growth Factor Nanocapsules with Tunable Controlled Release for Chronic Wound Healing (Small, 2024)
• [Retracted] Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway (Experimental and Therapeutic Medicine, 2024)
• Laminin and Platelet-Derived Growth Factor-BB Promote Neuronal Differentiation of Human Urine-Derived Stem Cells (Tissue Engineering and Regenerative Medicine, 2018)
• Expression of CD117 and platelet-derived growth factor receptor α in patients with alopecia areata (Indian Journal of Dermatology, Venereology and Leprology, 2020)
• Anti-inflammatory and Chondroprotective Effects of Platelet-derived Growth Factor-BB on Osteoarthritis Rat Models (Journals of Gerontology Series A, 2023)
• Clinical significance of platelet derived growth factor-C and -D in gastric cancer (Oncology Letters, 2015)